Avidity (RNA) Q2 Revenue Jumps 88%
Avidity Biosciences (NASDAQ:RNA), a biotechnology firm developing RNA-targeted therapeutics for rare muscle diseases, reported its second-quarter 2025 results on August 7, 2025. The period featured sharply higher revenue (GAAP) at $3.8 million, well above the $1.49 million average analyst estimate (GAAP), mainly from ongoing collaboration payments. At the same time, expenses (GAAP) jumped, with an earnings per share loss of $(1.21) (GAAP), coming in below expectations for $(0.96) GAAP EPS. The company reported an expanded net loss (GAAP) of $157.3 million as it accelerated late-stage research and increased commercial infrastructure. The quarter showcased both clear clinical progress and a heavy investment phase, positioning the company for several potential drug submissions over the next 18 months.
Source: Analyst estimates for the quarter provided by FactSet.
Avidity Biosciences works on creating novel medicines for rare neuromuscular diseases using its antibody oligonucleotide conjugate (AOC) platform. This technology joins antibodies—proteins that can target very specific cells—with RNA-targeted medicines, enabling delivery into muscle tissue. Success for the business depends on advancing its three core clinical programs through trials: del-desiran for myotonic dystrophy type 1, del-brax for facioscapulohumeral muscular dystrophy, and del-zota for Duchenne muscular dystrophy with exon 44 mutations.
Source Fool.com
